Profil
Jean-Patrick Demonsang is currently the Chairman of Demonsang Consulting SAS. Previously, he served as the Chief Executive Officer of Genode Partners SAS, Chairman of G1j Ile De France, and Chairman of Parexi SAS. From 2010 to 2013, he was the President & Managing Director of Seventure Partners SA. He also served as a Director at Natixis Venture Sélection SA and an Independent Director at Orphan Synergy Europe-Pharma SA. Demonsang holds an MBA from École des Hautes Études Commerciales de Paris.
Postes actifs de Jean-Patrick Demonsang
| Sociétés | Poste | Début |
|---|---|---|
Demonsang Consulting SAS | Président | - |
Anciens postes connus de Jean-Patrick Demonsang
| Sociétés | Poste | Fin |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Directeur/Membre du Conseil | 22/06/2023 |
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners invests in companies located in Israel, Asia and North America primarily in Europe. The firm targets companies operating in the fields of digital technologies and life sciences sectors. It provides financing for seed, early and growth stage capital requirements with an investment size of EUR 0.5 - 20 million. | Directeur Général | 01/01/2013 |
Natixis Venture Sélection SA
Natixis Venture Sélection SA Investment ManagersFinance Acts as Venture Capital Fund | Directeur/Membre du Conseil | - |
Genode Partners SAS | Directeur Général | - |
Parexi SAS
Parexi SAS MiscellaneousMiscellaneous Functions as an investment holding company | Président | - |
Formation de Jean-Patrick Demonsang
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners invests in companies located in Israel, Asia and North America primarily in Europe. The firm targets companies operating in the fields of digital technologies and life sciences sectors. It provides financing for seed, early and growth stage capital requirements with an investment size of EUR 0.5 - 20 million. | Finance |
École des Hautes Études Commerciales de Paris
École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Natixis Venture Sélection SA
Natixis Venture Sélection SA Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Demonsang Consulting SAS | |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
G1j Ile De France | |
Parexi SAS
Parexi SAS MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Genode Partners SAS |
















